Drug Patents owned by Merck
1. List of Emend drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(4 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 26 March, 2003
Treatment: Prevention of postoperative nausea and vomiting; For the prevention of nausea and vomiting associated with chemotherapy
Dosage: CAPSULE;ORAL
EMEND family patents
3
United States
1
ME
1
Yugoslavia
1
Poland
1
Dominican Republic
1
Canada
1
Georgia
1
Slovenia
1
Korea, Republic of
1
Ukraine
1
Brazil
1
Hong Kong
1
Taiwan
1
China
1
Iceland
1
Germany
1
Japan
1
Denmark
1
Croatia
1
Malaysia
1
Hungary
1
Argentina
1
Spain
1
Mexico
1
New Zealand
1
EA
1
Colombia
1
Australia
1
Norway
1
South Africa
1
Ecuador
1
Austria
1
Portugal
1
Israel
1
Jordan
1
Peru
1
European Union
2. List of Zolinza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7456219 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2027
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7652069 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(3 months ago) | |
| US8101663 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(3 months ago) | |
| US7732490 | MERCK | Methods of treating cancer |
Mar, 2023
(3 months ago) | |
| US8067472 | MERCK | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar, 2023
(3 months ago) | |
| US7851509 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Feb, 2024
(8 months from now) | |
| US7399787 | MERCK | Methods of treating cancer with HDAC inhibitors |
Feb, 2025
(1 year, 8 months from now) | |
| US8093295 | MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May, 2026
(2 years from now) | |
| US8450372 | MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Mar, 2028
(4 years from now) | |
Drugs and Companies using VORINOSTAT ingredient
Market Authorisation Date: 06 October, 2006
Treatment: Treatment of cutaneous manifestations in patients wtih cutaneous t-cell lymphoma (ctcl)
Dosage: CAPSULE;ORAL
ZOLINZA family patents
34
United States
10
European Union
9
Japan
9
Australia
8
New Zealand
7
China
6
Canada
5
Korea, Republic of
5
Russia
4
Norway
4
South Africa
3
Poland
3
Brazil
2
Ukraine
2
Taiwan
2
Morocco
2
Argentina
2
Spain
2
Mexico
2
Ecuador
2
Israel
1
Dominican Republic
1
Slovenia
1
Hong Kong
1
Costa Rica
1
Iceland
1
Germany
1
Cyprus
1
Denmark
1
Croatia
1
Malaysia
1
Nicaragua
1
Austria
1
Portugal
1
Peru
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic